Menu Search
Equities

Genprex Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0A8I:LSE

Genprex Inc

Actions
  • Price (USD)2.21
  • Today's Change0.16 / 7.80%
  • Shares traded8.96k
  • 1 Year change-91.29%
  • Beta-0.7227
Data delayed at least 20 minutes, as of Feb 06 2026 19:12 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.

  • Revenue in USD (TTM)0.00
  • Net income in USD-17.05m
  • Incorporated2009
  • Employees15.00
  • Location
    Genprex Inc3300 Bee Cave Road, Suite 650-227AUSTIN 78746United StatesUSA
  • Phone+1 (512) 537-7997
  • Fax+1 (302) 655-5049
  • Websitehttps://www.genprex.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.